Sergio Duron, Enlaza Therapeutics CEO

En­laza launch­es with $61M, aims to take co­va­len­cy in­to pro­tein drugs

Co­va­lent small mol­e­cule drug de­vel­op­ment has seen a bit of a re­nais­sance in re­cent years. But a new San Diego-based biotech wants to take co­va­len­cy one step fur­ther — in­to pro­tein drugs.

En­laza Ther­a­peu­tics launched out of stealth Thurs­day morn­ing with $61 mil­lion in fund­ing. The round was led by Aval­on Ven­tures, fol­lowed by Light­speed Ven­ture Part­ners, Fra­zier Life Sci­ences and Sam­sara Bio­Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.